Quantcast

Fc Protein and Glycoengineered Antibodies Market

March 5, 2014

DUBLIN, March 5, 2014 /PRNewswire/ –

Research and Markets (
http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and) has announced the
addition of the “Fc Protein and Glycoengineered Antibodies Market”
[http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and ] report to their
offering.

(Logo:
http://photos.prnewswire.com/prnh/20130307/600769 )

Engineered antibodies are antibody based therapeutics, which are gaining increasing
attention from both large and small pharmaceutical companies. Developed through
introduction of modifications in monoclonal antibodies, the aim is to develop antibodies
with improved efficacy.

Research done in the last decade to develop engineered antibodies has yielded a rich
knowledge base on how to develop and market these next generation antibodies. These
therapeutic antibodies seem to be more promising, with improved properties when compared
to their ancestors. There are several molecules in phase II / III clinical trials and a
few waiting for approvals. In addition, a large number of molecules are also in
pre-clinical trials and are expected to progress through various stages of drug
development over the next ten years.

The Fc Protein and Glycoengineered Antibody Market, 2013-2023 report was commissioned
to examine the various aspects of engineering an antibody to develop novel drugs and
address several oncology specific diseases. With the market being fairly new, the report
examines several elements of developing these next generation antibodies including
technologies used for their production, site of engineering in an antibody and molecules
in pipeline.

For the purposes of this report, engineered antibodies are defined as antibodies which
have been modified in their Fc region. The two types of modification considered are:

        - Fc Glycoengineering (referred to as Glycoengineering' in the report)
        - Fc Protein engineering

        Key Topics Covered:

        1. EXECUTIVE SUMMARY

        2. INTRODUCTION

        3. ENGINEERED ANTIBODIES: OVERVIEW AND BACKGROUND

        4. GLYCOENGINEERED ANTIBODIES MARKET, 2012 - 2023

        5. Fc PROTEIN ENGINEERED ANTIBODIES MARKET, 2013 - 2023

        6. TECHNOLOGICAL PLATFORMS FOR ENGINEERED ANTIBODIES

        7. PROFILES OF LEADING COMPANIES

        8. SWOT ANALYSIS

        9. CONCLUSIONS

        10. APPENDIX 1: TABLES

        11. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

Companies Mentioned:

        - ABN AMRO Capital
        - AVID Bioservices
        - Absolute Antibody
        - Accurus Biosciences
        - Affitech A/S
        - Allos Therapeutics
        - Amgen
        - Andromeda Biotech
        - Applied Molecular Evolution (AME)
        - Astra Zeneca
        - BioMedinvest
        - BioWa
        - BioXcellence
        - BioXpress Therapeutics
        - Bioceros
        - Biocon
        - Biogen Idec
        - Boehringer Ingelheim
        - Bristol Myers Squibb
        - CSL
        - Celltrion
        - Centocor Ortho Biotech
        - Cephalon
        - ChemoCentryx
        - Chugai Pharmaceuticals
        - Deutsche Venture Capital
        - Diamyd Medical
        - Dong-A Pharmaceutical
        - Eli Lilly
        - Eureka Therapeutics
        - Five Prime Therapeutics
        - GSK
        - Genentech
        - Gilde Investment Management
        - Global Life Science Ventures
        - Glycart
        - Glycode
        - Glycotope
        - Green Cross Corporation
        - Greenovation
        - Halozyme Therapeutics
        - Hanwha Chemical
        - Human Genome Sciences
        - ISU Abxis
        - Ildong Pharmaceuticals
        - ImmunGene
        - Inhibrx
        - InvivoGen
        - KaloBios
        - Kyowa Hakko Kirin
        - Laboratoire francais du Fractionnement et des Biotechnologies (LFB)
        - Life Science Pharmaceuticals
        - Lonza
        - MacroGenics
        - MedImmune
        - Meiji Seika Pharma
        - Mentrik Biotech
        - Merck-GlycoFi
        - Micromet
        - MilleGen
        - Minapharm Pharmaceuticals
        - Morphosys
        - Mylan
        - NKT Therapeutics
        - Nippon Kayaku
        - Nippon Shinyaku
        - Novartis
        - Novartis Venture Fund
        - Ortho-McNeil Janssen Pharmaceutical
        - PDL Biopharma
        - Pfizer
        - Pikamab
        - Pinnacle Oncology Hematology
        - PlantForm Corporation
        - ProStrakan
        - Quester Capital Management
        - Regeneron Pharmaceuticals
        - Roche
        - Sandoz
        - Sanofi
        - Schnell Biopharma
        - Seattle Genetics
        - Servier
        - Shanghai CP Guojian
        - SiaMedExpress
        - Sorrento Therapeutics
        - Synthon-Biolex
        - TG Therapeutics
        - Taiho Pharmaceutical
        - Teva Pharmaceuticals
        - Trubion
        - Vivalis
        - Watson Pharmaceuticals
        - WuXi AppTec
        - Xencor
        - Zymeworks
        - arGEN-X
        - biOasis Technologies
        - rEVO Biologic

For more information visit

http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


    Photo: 

http://photos.prnewswire.com/prnh/20130307/600769

SOURCE Research and Markets


Source: PR Newswire



comments powered by Disqus